pteridines has been researched along with Cancer of Lung in 26 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study investigated the feasibility of predicting the neutropenia-related effects of a therapy that combines the investigational drug BI 2536 (inhibitor of Polo-like kinase 1) and pemetrexed, an approved anticancer drug." | 7.76 | Prediction of neutropenia-related effects of a new combination therapy with the anticancer drugs BI 2536 (a Plk1 inhibitor) and pemetrexed. ( Döge, C; Freiwald, M; Fritsch, H; Munzert, G; Soto, E; Staab, A; Trocóniz, IF, 2010) |
| "By using a mouse model of osteosarcoma induced by paratibial injection of cells, we assessed the impact of Smad7 overexpression or SD-208 on tumor growth, tumor microenvironment, bone remodeling, and metastasis development." | 3.80 | Overexpression of smad7 blocks primary tumor growth and lung metastasis development in osteosarcoma. ( Amiaud, J; Bougras, G; Chesneau, J; Heymann, D; Heymann, MF; Lamora, A; Le Deley, MC; Leduc, M; Redini, F; Stresing, V; Talbot, J; Taurelle, J; Verrecchia, F, 2014) |
| "This study investigated the feasibility of predicting the neutropenia-related effects of a therapy that combines the investigational drug BI 2536 (inhibitor of Polo-like kinase 1) and pemetrexed, an approved anticancer drug." | 3.76 | Prediction of neutropenia-related effects of a new combination therapy with the anticancer drugs BI 2536 (a Plk1 inhibitor) and pemetrexed. ( Döge, C; Freiwald, M; Fritsch, H; Munzert, G; Soto, E; Staab, A; Trocóniz, IF, 2010) |
| "Volasertib is a potent, selective, cell cycle kinase inhibitor that induces mitotic arrest and apoptosis by targeting Polo-like kinase." | 2.80 | A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer. ( Blais, N; Chu, Q; Ellis, PM; Gu, Y; Hirsh, V; Leighl, NB; Liu, D; Pilz, K; Reaume, MN; Sadrolhefazi, B; Wierzbicki, R, 2015) |
| "BI 2536 is a potent, highly selective inhibitor of polo-like kinase (Plk) 1." | 2.78 | A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer. ( Chu, QS; Ellis, PM; Fritsch, H; Gaschler-Markefski, B; Gyorffy, S; Laurie, SA; Leighl, N; Munzert, G, 2013) |
| " Grade 4 neutropenia occurred in 37% of patients; common nonhematologic adverse events were fatigue (31%) and nausea (27%)." | 2.75 | The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. ( Frickhofen, N; Fritsch, H; Gaschler-Markefski, B; Hanft, G; Kortsik, C; Munzert, G; Reck, M; Schuler, M; Sebastian, M; von Pawel, J; Waller, CF, 2010) |
| "The prognosis of small cell lung cancer (SCLC) is poor despite its good initial response to chemotherapy." | 1.48 | Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer. ( Lu, G; Wang, Y; Wu, L; Xu, L; Yao, Y; Zhou, J, 2018) |
| " First, BI 6727 has a pharmacokinetic profile favoring sustained exposure of tumor tissues with a high volume of distribution and a long terminal half-life in mice (V(ss) = 7." | 1.35 | BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. ( Adolf, GR; Baum, A; Garin-Chesa, P; Grauert, M; Haslinger, C; Hoffmann, M; Quant, J; Rudolph, D; Steegmaier, M, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.85) | 18.2507 |
| 2000's | 3 (11.54) | 29.6817 |
| 2010's | 19 (73.08) | 24.3611 |
| 2020's | 3 (11.54) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, J | 2 |
| Yang, Q | 1 |
| Lu, L | 1 |
| Tuo, Z | 1 |
| Shou, Z | 1 |
| Cheng, J | 1 |
| Abdulrahman, N | 2 |
| Siveen, KS | 1 |
| Joseph, JM | 1 |
| Osman, A | 1 |
| Yalcin, HC | 1 |
| Hasan, A | 1 |
| Uddin, S | 1 |
| Mraiche, F | 2 |
| Park, S | 1 |
| Kim, TM | 1 |
| Cho, SY | 1 |
| Kim, S | 1 |
| Oh, Y | 1 |
| Kim, M | 1 |
| Keam, B | 1 |
| Kim, DW | 1 |
| Heo, DS | 1 |
| Breitenbuecher, F | 1 |
| von Pawel, J | 2 |
| Sebastian, M | 2 |
| Kortsik, C | 2 |
| Ting, S | 1 |
| Kasper, S | 1 |
| Wohlschläger, J | 1 |
| Worm, K | 1 |
| Morresi-Hauf, A | 1 |
| Schad, A | 1 |
| Westerwick, D | 1 |
| Wehler, B | 1 |
| Werner, M | 1 |
| Munzert, G | 6 |
| Gaschler-Markefski, B | 3 |
| Schmid, KW | 1 |
| Schuler, M | 2 |
| Yao, D | 1 |
| Gu, P | 1 |
| Wang, Y | 4 |
| Luo, W | 1 |
| Chi, H | 1 |
| Ge, J | 1 |
| Qian, Y | 1 |
| Wu, L | 2 |
| Yao, Y | 1 |
| Lu, G | 1 |
| Xu, L | 1 |
| Viswanath, P | 2 |
| Peng, S | 3 |
| Singh, R | 3 |
| Kingsley, C | 1 |
| Balter, PA | 1 |
| Johnson, FM | 4 |
| Van den Bossche, J | 1 |
| Deben, C | 1 |
| De Pauw, I | 1 |
| Lambrechts, H | 1 |
| Hermans, C | 1 |
| Deschoolmeester, V | 1 |
| Jacobs, J | 1 |
| Specenier, P | 1 |
| Pauwels, P | 1 |
| Vermorken, JB | 1 |
| Peeters, M | 1 |
| Lardon, F | 1 |
| Wouters, A | 1 |
| Sambandam, V | 1 |
| Shen, L | 1 |
| Rao, X | 1 |
| Fang, B | 1 |
| Wang, J | 3 |
| Zhou, W | 1 |
| Liu, X | 1 |
| Tu, Z | 1 |
| Zhang, L | 1 |
| Ku, X | 1 |
| Bai, F | 1 |
| Zhao, Z | 1 |
| Xu, Y | 1 |
| Ding, K | 1 |
| Li, H | 1 |
| Lamora, A | 1 |
| Talbot, J | 1 |
| Bougras, G | 1 |
| Amiaud, J | 1 |
| Leduc, M | 1 |
| Chesneau, J | 1 |
| Taurelle, J | 1 |
| Stresing, V | 1 |
| Le Deley, MC | 1 |
| Heymann, MF | 1 |
| Heymann, D | 1 |
| Redini, F | 1 |
| Verrecchia, F | 1 |
| Choi, M | 1 |
| Kim, W | 1 |
| Cheon, MG | 1 |
| Lee, CW | 1 |
| Kim, JE | 1 |
| Ellis, PM | 2 |
| Leighl, NB | 1 |
| Hirsh, V | 1 |
| Reaume, MN | 1 |
| Blais, N | 1 |
| Wierzbicki, R | 1 |
| Sadrolhefazi, B | 1 |
| Gu, Y | 1 |
| Liu, D | 1 |
| Pilz, K | 1 |
| Chu, Q | 1 |
| Ferrarotto, R | 1 |
| Goonatilake, R | 2 |
| Yoo, SY | 1 |
| Tong, P | 2 |
| Giri, U | 2 |
| Minna, J | 1 |
| Girard, L | 1 |
| Wang, L | 2 |
| Li, L | 2 |
| Diao, L | 1 |
| Peng, DH | 1 |
| Gibbons, DL | 1 |
| Glisson, BS | 1 |
| Heymach, JV | 2 |
| Byers, LA | 1 |
| Jaballah, M | 1 |
| Poomakkoth, N | 1 |
| Riaz, S | 1 |
| Abdelaziz, S | 1 |
| Issa, A | 1 |
| Nilsson, M | 1 |
| Villalobos, P | 1 |
| Mino, B | 1 |
| Rodriguez-Canales, J | 1 |
| Wistuba, I | 1 |
| Kato, T | 1 |
| Lee, D | 1 |
| Patel, P | 1 |
| Young, AJ | 1 |
| Wada, H | 1 |
| Hu, HP | 1 |
| Ujiie, H | 1 |
| Kaji, M | 1 |
| Kano, S | 1 |
| Matsuge, S | 1 |
| Domen, H | 1 |
| Kanno, H | 1 |
| Hatanaka, Y | 1 |
| Hatanaka, KC | 1 |
| Kaga, K | 1 |
| Matsui, Y | 1 |
| Matsuno, Y | 1 |
| De Perrot, M | 1 |
| Yasufuku, K | 1 |
| Awad, MM | 1 |
| Chu, QS | 2 |
| Gandhi, L | 1 |
| Stephenson, JJ | 1 |
| Govindan, R | 1 |
| Bradford, DS | 1 |
| Bonomi, PD | 1 |
| Ellison, DM | 1 |
| Eaton, KD | 1 |
| Fritsch, H | 4 |
| Johnson, BE | 1 |
| Socinski, MA | 1 |
| Rudolph, D | 1 |
| Steegmaier, M | 1 |
| Hoffmann, M | 1 |
| Grauert, M | 1 |
| Baum, A | 1 |
| Quant, J | 1 |
| Haslinger, C | 1 |
| Garin-Chesa, P | 1 |
| Adolf, GR | 1 |
| Gibbons, SE | 1 |
| Stayton, I | 1 |
| Ma, Y | 1 |
| Reck, M | 1 |
| Waller, CF | 1 |
| Frickhofen, N | 1 |
| Hanft, G | 1 |
| Soto, E | 2 |
| Staab, A | 2 |
| Freiwald, M | 2 |
| Döge, C | 1 |
| Trocóniz, IF | 2 |
| Doege, C | 1 |
| Leighl, N | 1 |
| Laurie, SA | 1 |
| Gyorffy, S | 1 |
| Ruan, JW | 1 |
| Huang, JF | 1 |
| Fu, LW | 1 |
| Huang, ZS | 1 |
| Ma, L | 1 |
| Gu, LQ | 1 |
| Merz, KH | 1 |
| Marko, D | 1 |
| Regiert, T | 1 |
| Reiss, G | 1 |
| Frank, W | 1 |
| Eisenbrand, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised Open-label Phase II Trial of BI 6727 Monotherapy and BI 6727 in Combination With Standard Dose Pemetrexed Compared to Pemetrexed Monotherapy in Second Line Non-small Cell Lung Cancer[NCT00824408] | Phase 2 | 143 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CL - total clearance of pemetrexed in plasma after IV administration (NCT00824408)
Timeframe: 5 minutes before pemetrexed infusion, at the end of the infusion and 1.5 hours (h), 2.5h, 4.5h and 25.5h after the end of pemetrexed infusion
| Intervention | mL/min (Geometric Mean) |
|---|---|
| Volasertib 250 mg + Pemetrexed 500 mg/m2 | 54.4 |
| Volasertib 300 mg + Pemetrexed 500 mg/m2 | 69.1 |
Cmax - maximum measured concentration of pemetrexed in plasma (NCT00824408)
Timeframe: 5 minutes before pemetrexed infusion, at the end of the infusion and 1.5 hours (h), 2.5h, 4.5h and 25.5h after the end of pemetrexed infusion
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Volasertib 250 mg + Pemetrexed 500 mg/m2 | 131000 |
| Volasertib 300 mg + Pemetrexed 500 mg/m2 | 115000 |
Cmax - maximum measured concentration of volasertib in plasma. (NCT00824408)
Timeframe: 5 minutes (min) before the start of Volasertib infusion and 1 hour (h), 2h, 4h, 24h, 168h and 336h after the start of Volasertib infusion
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Volasertib 250 mg + Pemetrexed 500 mg/m2 | 554 |
| Volasertib 300 mg + Pemetrexed 500 mg/m2 | 635 |
| Volasertib 300 mg | 565 |
The duration of overall response was measured from the time measurement criteria were met for CR or PR (whichever was first recorded) until the first date that recurrent or progressive disease (PD) was objectively documented (taking as reference for PD the smallest measurements recorded since treatment began). The duration of overall CR was measured from the time measurement criteria were first met for CR until the first date that recurrent disease was objectively documented. Duration of disease control is presented here. (NCT00824408)
Timeframe: From the time measurement criteria were met for CR or PR (whichever was first recorded) until the first date that recurrent or progressive disease was objectively documented
| Intervention | weeks (Median) |
|---|---|
| Randomization Phase: Volasertib 300 mg | 23.0 |
| Randomization Phase: Volasertib 300 mg + Pemetrexed 500 mg/m2 | 19.6 |
| Randomization Phase: Pemetrexed 500 mg/m2 | 23.4 |
"Occurence of Dose-limiting toxicity (DLT). A DLT was defined as one or more of the following:~treatment-related CTCAE Grade 3 or 4 nonhematological toxicity (except emesis or diarrhea responding to supportive treatment).~treatment-related CTCAE Grade 4 neutropenia for ≥7 days and/or complicated by infection.~CTCAE Grade 4 thrombocytopenia." (NCT00824408)
Timeframe: Patients were treated for repeated 21-day treatment cycles until disease progression or intolerability of the trial drug, whichever occurred first.
| Intervention | participants (Number) |
|---|---|
| Run-in Phase: Volasertib 250 mg + Pemetrexed 500 mg/m2 | 1 |
| Run-in Phase: Volasertib 300 mg + Pemetrexed 500 mg/m2 | 1 |
Overall survival (OS) was defined as the duration of time from randomization to time of death. (NCT00824408)
Timeframe: From randomization until time of death
| Intervention | months (Median) |
|---|---|
| Randomization Phase: Volasertib 300 mg | 22.9 |
| Randomization Phase: Volasertib 300 mg + Pemetrexed 500 mg/m2 | 17.1 |
| Randomization Phase: Pemetrexed 500 mg/m2 | 17.4 |
"Disease progression was defined according to the Response Evaluation Criteria in Solid Tumours (RECIST)) criteria. Progression-free survival time was calculated as the duration from the date of randomization to the date of disease progression or death, whichever occured first. For patients with known date of progression (or death): PFS [days] = min (date of progression, date of death) - date of randomization + 1 day. For patients without progression or death, PFS was censored at the last imaging date that showed no disease progression: PFS [days, censored] = date of last imaging showing no progression - date randomization + 1 day.~The number of participants analysed displays the number of patients with an event (progression)." (NCT00824408)
Timeframe: From randomization until disease progression or death
| Intervention | months (Median) |
|---|---|
| Randomization Phase: Volasertib 300 mg | 1.4 |
| Randomization Phase: Volasertib 300 mg + Pemetrexed 500 mg/m2 | 3.3 |
| Randomization Phase: Pemetrexed 500 mg/m2 | 5.3 |
CL - total clearance of volasertib in plasma after IV administration (NCT00824408)
Timeframe: 5 minutes (min) before the start of Volasertib infusion and 1 hour (h), 2h, 4h, 24h, 168h and 336h after the start of Volasertib infusion
| Intervention | mL/min (Geometric Mean) |
|---|---|
| Volasertib 250 mg + Pemetrexed 500 mg/m2 | 782 |
| Volasertib 300 mg + Pemetrexed 500 mg/m2 | 882 |
| Volasertib 300 mg | 867 |
Vss - apparent volume of distribution at steady state following IV administration of pemetrexed (NCT00824408)
Timeframe: 5 minutes before pemetrexed infusion, at the end of the infusion and 1.5 hours (h), 2.5h, 4.5h and 25.5h after the end of pemetrexed infusion
| Intervention | Litres (Geometric Mean) |
|---|---|
| Volasertib 250 mg + Pemetrexed 500 mg/m2 | 9.40 |
| Volasertib 300 mg + Pemetrexed 500 mg/m2 | 13.1 |
Vss - apparent volume of distribution at steady state following IV administration of volasertib (NCT00824408)
Timeframe: 5 minutes (min) before the start of Volasertib infusion and 1 hour (h), 2h, 4h, 24h, 168h and 336h after the start of Volasertib infusion
| Intervention | Litres (Geometric Mean) |
|---|---|
| Volasertib 250 mg + Pemetrexed 500 mg/m2 | 6730 |
| Volasertib 300 mg + Pemetrexed 500 mg/m2 | 6750 |
| Volasertib 300 mg | 6230 |
Frequency of patients with possible clinically significant abnormalities (NCT00824408)
Timeframe: From first drug infusion until 21 days after last drug infusion, up to 1100 days
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Haemoglobin - Low | White blood cell ct. - Low | White blood cell ct. - High | Platelets - Low | Platelets - High | Neutrophils - Low | Lymphocytes - Low | AST/GOT, SGOT - High | ALT/GPT, SGPT - High | Alkaline phosphatase - High | Creatinine - High | Bilirubin, total - High | |
| Randomization Phase: Pemetrexed 500 mg/m2 | 14 | 12 | 1 | 2 | 3 | 12 | 22 | 3 | 6 | 5 | 0 | 1 |
| Randomization Phase: Volasertib 300 mg | 16 | 15 | 1 | 8 | 3 | 13 | 16 | 0 | 0 | 0 | 0 | 1 |
| Randomization Phase: Volasertib 300 mg + Pemetrexed 500 mg/m2 | 21 | 25 | 0 | 3 | 0 | 23 | 22 | 6 | 10 | 0 | 3 | 1 |
| Run-in Phase: Volasertib 250 mg + Pemetrexed 500 mg/m2 | 1 | 4 | 0 | 0 | 0 | 4 | 4 | 0 | 0 | 0 | 0 | 1 |
| Run-in Phase: Volasertib 300 mg + Pemetrexed 500 mg/m2 | 2 | 2 | 0 | 1 | 1 | 2 | 4 | 1 | 1 | 0 | 0 | 0 |
Objective tumor response, defined as complete response (CR), and partial response (PR), evaluated according to RECIST criteria. Evaluation of target lesions: Complete Response (CR): disappearance of all target lesions. Partial Response (PR): ≥30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. Evaluation of nontarget lesions: Complete Response (CR): disappearance of all nontarget lesions. (NCT00824408)
Timeframe: From first drug infusion until 21 days after last drug infusion, up to 1100 days
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Complete response (CR) | Partial response (PR) | |
| Randomization Phase: Pemetrexed 500 mg/m2 | 0.0 | 10.6 |
| Randomization Phase: Volasertib 300 mg | 0.0 | 8.1 |
| Randomization Phase: Volasertib 300 mg + Pemetrexed 500 mg/m2 | 0.0 | 21.3 |
| Run-in Phase: Volasertib 250 mg + Pemetrexed 500 mg/m2 | 0.0 | 16.7 |
| Run-in Phase: Volasertib 300 mg + Pemetrexed 500 mg/m2 | 0.0 | 50.0 |
All patients were carefully monitored during and after each treatment cycle. Adverse events (AEs) were recorded and were graded according to the National Cancer Institute - Common Terminology Criteria for Adverse Events (CTCAE). (NCT00824408)
Timeframe: From first drug infusion until 21 days after last drug infusion, up to 1100 days
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| CTCAE Grade 1 | CTCAE Grade 2 | CTCAE Grade 3 | CTCAE Grade 4 | CTCAE Grade 5 | |
| Randomization Phase: Pemetrexed 500 mg/m2 | 6 | 18 | 15 | 5 | 0 |
| Randomization Phase: Volasertib 300 mg | 6 | 12 | 8 | 6 | 3 |
| Randomization Phase: Volasertib 300 mg + Pemetrexed 500 mg/m2 | 2 | 18 | 19 | 5 | 2 |
| Run-in Phase: Volasertib 250 mg + Pemetrexed 500 mg/m2 | 0 | 0 | 3 | 3 | 0 |
| Run-in Phase: Volasertib 300 mg + Pemetrexed 500 mg/m2 | 0 | 2 | 3 | 1 | 0 |
6 trials available for pteridines and Cancer of Lung
| Article | Year |
|---|---|
Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536.
Topics: Antimitotic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progr | 2017 |
A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Drug Dosage Cal | 2015 |
An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).
Topics: Administration, Intravenous; Adult; Aged; Cell Cycle Proteins; Disease-Free Survival; Female; Humans | 2017 |
The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; | 2010 |
Comparison of different semi-mechanistic models for chemotherapy-related neutropenia: application to BI 2536 a Plk-1 inhibitor.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Humans; Lung Neoplasms; | 2011 |
A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer.
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2013 |
20 other studies available for pteridines and Cancer of Lung
| Article | Year |
|---|---|
PLK1 Inhibition Induces Immunogenic Cell Death and Enhances Immunity against NSCLC.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Humans; Immunogenic | 2021 |
Inhibition of p90 ribosomal S6 kinase potentiates cisplatin activity in A549 human lung adenocarcinoma cells.
Topics: A549 Cells; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autop | 2020 |
Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cel | 2020 |
Inhibiting polo-like kinase 1 enhances radiosensitization via modulating DNA repair proteins in non-small-cell lung cancer.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Chromosome Segrega | 2018 |
Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.
Topics: Animals; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; DNA Damage; Female; G | 2018 |
A Novel Method for Quantifying Total Thoracic Tumor Burden in Mice.
Topics: Animals; Antineoplastic Agents; Lung Neoplasms; Male; Mice, Inbred Strains; Mice, Transgenic; Neopla | 2018 |
In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
Topics: A549 Cells; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell | 2019 |
Non-canonical cMet regulation by vimentin mediates Plk1 inhibitor-induced apoptosis.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Drug Resi | 2019 |
Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Computational Biology | 2013 |
Overexpression of smad7 blocks primary tumor growth and lung metastasis development in osteosarcoma.
Topics: Animals; Bone Neoplasms; Bone Resorption; Cell Line, Tumor; Disease Models, Animal; Female; Gene Exp | 2014 |
Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells.
Topics: Antimitotic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle Protein | 2015 |
Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
Topics: Animals; Apoptosis; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Cyc | 2016 |
Inhibition of p90 ribosomal S6 kinase attenuates cell migration and proliferation of the human lung adenocarcinoma through phospho-GSK-3β and osteopontin.
Topics: Adenocarcinoma; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glycogen | 2016 |
Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle | 2016 |
SORORIN and PLK1 as potential therapeutic targets in malignant pleural mesothelioma.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Cell Cycle | 2016 |
BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell C | 2009 |
Optimization of urinary pteridine analysis conditions by CE-LIF for clinical use in early cancer detection.
Topics: Drug Stability; Early Detection of Cancer; Electrophoresis, Capillary; Humans; Lung Neoplasms; Pteri | 2009 |
Prediction of neutropenia-related effects of a new combination therapy with the anticancer drugs BI 2536 (a Plk1 inhibitor) and pemetrexed.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Smal | 2010 |
[Synthesis and antitumour activities of some pteridine derivatives].
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Humans; KB Cells; Lung Neoplasms; Molecular | 2004 |
Synthesis of 7-benzylamino-6-chloro-2-piperazino-4-pyrrolidinopteridine and novel derivatives free of positional isomers. Potent inhibitors of cAMP-specific phosphodiesterase and of malignant tumor cell growth.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Antineoplastic Agents; Cell Division; Crystallography, | 1998 |